SKN | Novavax Stock Faces a New Test as Vaccine Licensing Replaces the Traditional IPO Growth Story
Novavax, Inc. is pursuing a more capital-efficient future built around vaccine licensing, strategic partnerships and its proprietary Matrix-M adjuvant technology. Listed on Nasdaq under...
SKN | International IPO Market Weakens as Firmus Withdraws Australian Listing Plans
International IPO markets extended their declines in the week ended October 9, 2026, as the Renaissance International IPO Index fell 1.8%, underperforming the ACWX...
SKN | Crown Castle Stock Jumps 15.60% as Shares Climb Toward $80
Crown Castle Inc. , a real estate investment trust specializing in wireless communications infrastructure, closed at $79.64 on October 9, 2026, gaining $10.75, or...
SKN | City Therapeutics Sets Terms for $175 Million IPO as RNAi Pipeline Advances
City Therapeutics, a clinical-stage biotechnology company developing RNA interference therapies, has announced terms for an initial public offering that could raise $175 million. The...
SKN | TRex Bio Raises $117 Million in Nasdaq IPO to Advance Autoimmune Disease Treatments
TRex Bio, a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory diseases, has raised $117 million in its initial public offering, pricing 8.3...